Completed PHASE3 INTERVENTIONAL NCT00036608

A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine

Sponsor: Bristol-Myers Squibb

Interventions Entecavir

Updated 7 times since 2017 Last updated: Apr 7, 2011 Started: Jan 31, 2002 Primary completion: Feb 28, 2005 Completion: Feb 28, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00036608, this PHASE3 trial focuses on Chronic Hepatitis B and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 7 times since 2002, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Birmingham, United States , Boston, United States , Charlotte, United States , Chicago, United States , Cleveland, United States , Dallas, United States , Dundalk, United States , Durham, United States and 24 more locations